tiprankstipranks
Catalyst Pharmaceuticals price target raised to $36 from $30 at Truist
The Fly

Catalyst Pharmaceuticals price target raised to $36 from $30 at Truist

Truist raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $36 from $30 and keeps a Buy rating on the shares. The company’s Q3 results are “impressive” and represent the relentless pursuit of LEMS patient identification that is driving continued growth of Firdapse six years after launch, the analyst tells investors in a research note.

Don't Miss Our Christmas Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App